Details of the Drug
General Information of Drug (ID: DMFZBMQ)
Drug Name |
CHLOROXINE
|
|||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
chloroxine; 5,7-Dichloroquinolin-8-ol; 773-76-2; 5,7-Dichloro-8-hydroxyquinoline; Chlorquinol; Quixalin; Capitrol; Dichloroxin; Chloroxyquinoline; Dichloroquinolinol; Dikhloroskin; 5,7-Dichloro-8-quinolinol; Endiaron; Clofuzid; Quinolor; Dichlorohydroxyquinoline; Chlofucid; Quesyl; 5,7-Dichloroxine; 5,7-Dichlorooxine; Chlorohydroxyquinoline; 8-QUINOLINOL, 5,7-DICHLORO-; 5,7-Dichloro-8-oxyquinoline; Chloroxine [USAN]; 5,7-Dichlor-8-hydroxychinolin; C9H5Cl2NO; NSC 3904; UNII-2I8BD50I8B; CCRIS 5751; CHQ; Capitrol Cream Shampoo; EINECS 212-2
|
|||||||||||||||||||||||||||||||||||
Indication |
|
|||||||||||||||||||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||||||||||||||||||
Structure | ||||||||||||||||||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 214.04 | ||||||||||||||||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.5 | |||||||||||||||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | |||||||||||||||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | |||||||||||||||||||||||||||||||||||
ADMET Property |
|
|||||||||||||||||||||||||||||||||||
Adverse Drug Reaction (ADR) |
|
|||||||||||||||||||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||||||||||||||||||
Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | |||||||||||||||||||||||||||||||||||
Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | |||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug Off-Target (DOT) |
|
||||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Erythema | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | ME64.0 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
---|---|---|---|---|---|
2 | Chloroxine FDA Label | ||||
3 | Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches | ||||
4 | ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899. | ||||
5 | In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. | ||||